Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Number To Know…76,000,000

Executive Summary

$76m is the size of regenerative medicine specialist MiMedx's share purchase reprogram, which has just been expanded after its board decided it was "a favorable investment" for the company.

$76m is the size of MiMedx's share repurchase program after its board of directors this month authorized for the amount to be expanded by an additional $10m.

MiMedx specializes in regenerative biomaterials and bioimplants processed from human amniotic membrane. It has a number of products cleared for marketing by US FDA, including EpiFix, which is cleared for treating diabetic foot ulcers and chronic venous ulcers, and is in preclinical trial to assess its use in cardiovascular disease. It also has in development other products for orthopedic and cardiovascular indications. MiMedx said that in light of the prevailing market conditions, the company's available resources and other factors, the board believes the stock repurchases are a favorable investment for the company.

Meddevicetracker subscribers can access a profile of MiMedx, including data on its product portfolio, here.

Not a subscriber? Click here to request your free demo.






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts